BEIJING: Following the United Arab Emirates (UAE), Bahrain is the second country to approve a Chinese vaccine for COVID-19, announcing on Sunday that it has approved a vaccine developed by the China National Biotec Group (CNBG) under the China National Pharmaceutical Group (Sinopharm).
Analysts said the move will help more countries, especially American and European countries, to step out of political bias and increase their trust in Chinese vaccines.
Bahrain’s National Health Regulatory Authority approved the vaccine after reviewing data from Phase III clinical trials in several countries that showed 86 percent efficacy, media reported Sunday.
The vaccine also showed a 99 percent seroconversion rate of neutralizing antibodies and 100 percent effectiveness in preventing moderate and severe cases of the disease, according to media reports.
The figure was the same as that revealed by the UAE a few days ago of a candidate developed by CNBG’s Beijing Institute of Biological Product, which the UAE approved on December 9.
Bahraini health authorities did not clarify which of the two CNBG vaccines it approved, but experts reached by the Global Times guessed it was the one developed by the Beijing institute.
The figures look good vaccines based on inactivated virus, experts said.
– The Daily Mail-Global Times News exchange item
